Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, thereby disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses, as well as related innate and adaptive immunity pathways [1] [2].
説明 | Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that inhibits the FcRn-IgG interaction, thereby disrupting IgG homeostasis and impeding FcRn-mediated adaptive immune responses, as well as related innate and adaptive immunity pathways [1] [2]. |
In vitro | Orilanolimab at concentrations of 10nM, 50nM, and 100nM administered over 48 hours, inhibits the production of CD11c+ IFN-γ in B2M TG/TG FCGRT TG/TG Fcgrt -/- mice [1]. |
In vivo | Orilanolimab (20mg/kg; intravenous injection) significantly reduced plasma concentrations of HuLys11 in a murine model [1]. Dose-dependent and specific reductions in the circulating levels of IgG in cynomolgus monkeys were observed following orilanolimab administration (10-100 mg/kg; intravenous injection; every 5 weeks) [1]. |
別名 | SYNT001 |
分子量 | N/A |
CAS No. | 2066544-85-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Orilanolimab 2066544-85-0 SYNT-001 SYNT 001 SYNT001 Inhibitor inhibitor inhibit